| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2024―Nov―05 |
Elevated Interleukin-6 (IL-6) Levels with Ig (G & M) Antibodies in the Recovery Phase of Patients with COVID-19: Indication of Cytokine Storm and Re-infection |
John Bolodeoku, Terry Gbaa |
| 2 |
[GO] |
2024―Jun―24 |
Targeting Lipid Metabolism for Better Management of Coronavirus SARS-COV-2 Infections: Intervention, Antiviral Drug Development, and Challenges |
Yuting Wang, Peiran Chen, Ming-Liang He |
| 3 |
[GO] |
2023―Okt―24 |
Presence of Elevated Interleukin - 6 (IL-6) in the Blood of COVID-19 Convalescent Patients (40 - 93 Days) Post Onset of Symptoms Could be an Indicator of Ongoing Activation of the Immune System |
J Bolodeoku, C Anyaeche, M Bass, TK Kim |
| 4 |
[GO] |
2023―Mai―19 |
Novel Drug Development for Treatment of COVID-19 by In Silico Analysis: Identification of SARS-Cov-2 Inhibiting Streptomyces Compounds |
Jayant Kumar, Prachiti Gholap, Thulasi G Pillai |
| 5 |
[GO] |
2023―Mrz―07 |
Purinergic P2X7 Receptor as a Potential Targeted Therapy for COVID-19-associated Lung Cancer Progression |
Hamidreza Zalpoor, Abdullatif Akbari, Mohsen Nabi-Afjadi, Ali Norouzi, Farhad Seif, Majid Pornour |
| 6 |
[GO] |
2021―Jul―06 |
Ectodomain Shedding May Play a Pivotal Role in Disease Severity in COVID-19 |
|
| 7 |
[GO] |
2021―Mrz―25 |
Possible Therapeutic Use of Natural Compounds Against COVID-19 |
|
| 8 |
[GO] |
2020―Jun―25 |
COVID-19 Clinical Research |
|
